Objectives-The frequency
activity was measured in blood samples, and results were evaluated for TSD and Sandhoff disease heterozygosity. Samples from the TSD heterozygotes were also subjected to mutation analysis. Results-Of the 1260 samples studied, 22 (1 in 57; CI 1 in 41, 1 in 98) were identified as TSD heterozygotes by enzymatic analyses and 11 subjects (1 in 114; CI 1 in 72, 1 in 280) were identified as Sandhoff disease heterozygotes. Three of the 22 TSD heterozygotes were found to have benign pseudodeficiency mutations, resulting in a maximum TSD heterozygote frequency of 19 in 1260 (1 in 66; CI I in 46, 1 in 120). Together, these data provide a maximum frequency of heterozygosity for TSD or Sandhoff disease erao in 1260 (1 in 42; CI 1 in 31, 1 in 64) in this population. Conclusions-Simultaneous screening for TSD and Sandhoff disease heterozygosity by assay of P hexosaminidases A and B activities provides a possible method for use with subjects of French Canadian background. The relevance of some of the novel mutations identified in this group needs further study. However, the comparatively high combined frequency of TSD and Sandhoff disease heterozygosity indicates a need for discussion regarding the appropriateness of carrier testing for these disorders for persons of French Canadian background in Massachusetts. (Journal ofMedical Screening 1997; 4:133-136) Keywords: Tay-Sachs disease; Sandhoff disease; French Canadians Tay-Sachs disease (TSD) is an autosomal recessive lysosomal storage disease caused by a deficiency of lysosomal~hexosaminidase A (hex A) activity. I 2 Hex A consists of one a and one~subunit, and TSD results from mutations in the hex A gene that encodes the a subunit. Hex A deficiency causes the lysosomal accumulation of G M2 ganglioside in neuronal cells. Neurodegeneration and death occur in early childhood in the most severe (infantile) form of TSD; less severe juvenile and adult onset forms of TSD also exist. 1 2 Different hex A mutations have been associated with different amounts of residual hex A activity, and consequently, with different forms of TSD. 3 4 TSD heterozygote frequency has been estimated to be between I in 170 to I in 300 in the general non-Jewish population, with biochemical (enzyme activity) data associated with the higher frequency and estimation from birth prevalence of the disease yielding the lower frequency. 1 5 This discrepancy is thought to result from the existence of pseudodeficiency mutations in the hex A gene that have low in vitro activity, but do not seem to cause disease in vivo.· 7 Therefore, the true general population frequency of deleterious hex A mutations is probably about I in 300. [5] [6] [7] Heterozygosity for TSD occurs with increased frequency among persons of Ashkenazi (Central and Eastern European) Jewish ethnicity" and French Canadians in eastern Quebec." The heterozygote frequency in the Ashkenazi Jewish population is approximately 1 in 25, based on biochemical and incidence data. 1 5 9 10 Three mutations account for 95-98% of the TSD alleles found in Ashkenazi Jews.' 11 Because of the frequent occurrence of heterozygosity for this severe neurodegenerative condition among persons of Ashkenazi Jewish ethnicity, it is standard medical practice to offer heterozygote testing for TSD to persons of this background."
Heterozygosity for TSD among unrelated French Canadians in parts of eastern Quebec has been estimated to be I in 13, whereas the frequency among French Canadians living in Montreal was determined to be approximately 1 in 300,0 similar to the general population frequency. Several mutations that cause TSD have been identified in the French Canadian population of Quebec, with the most common being a 7.6 kb deletion in the 5' end of the hex A gene." 13 A related disorder, Sandhoff disease, is caused by mutations in the hex B gene that encodes the~subunit of~hexosaminidase, a Excerpts from the patient questionnaire Are you (circle as many as apply)?:
Ashkenazi-Jewish French Canadian Franco-American Other ing diseases in this population. This report details a prospective study designed to define the TSD and Sandhoff disease heterozygote frequencies among persons of French Canadian background living in Massachusetts. subunit common to both hex A and hex B; hex B is composed of two~subunits. Consequently, Sandhoff disease is characterised biochemically by deficiencies of both hex A and hex B activities with resultant accumulation of both G M2 ganglioside and N-acetylglucosamine containing oligosaccharides in tissues. I The clinical picture of classic Sandhoff disease is similar to that of infantile TSD; other, later onset clinical forms of Sandhoff disease have also been described. I Several cases of Sandhoff disease have been reported in the French Canadian population. I 9 In 1980, an estimated 350 000 persons of French Canadian ancestry lived in New England," and it has been estimated that at least 10% of the current population of New England is of French Canadian background." In some regions of New England, the percentage of Franco-Americans is much higher. For example, about 25% of the New Hampshire population is of French Canadian background. 15 Several cities in Massachusetts, such as Fall River, Worcester, Lowell, and others, also have a large representation of people with French Canadian heritage. 15 TSD heterozygotes of French Canadian background have been identified in New England, and mutation analysis of some of those carriers disclosed disease causing mutations previously identified among French Canadians in eastern Quebec, as well as some novel mutations."
No prospective analysis of the frequency of heterozygosity for TSD or Sandhoff disease among French Canadians in any of the New England states has been done previously. An increased prevalence of heterozygosity for these disorders in New Englanders with French Canadian background would be a significant public health issue and would have significant ramifications for the medical care and counselling offered to these people. Consequently, it is important to determine the frequency of heterozygosity for these devastat-
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Methods
SAMPLES
Samples for analysis were referred to the Shriver Center Tay-Sachs Disease Prevention Program for determination of TSD heterozygosity. Persons of French Canadian background were identified by their responses to queries on the questionnaire routinely used by the programme (fig 1) . Persons who selfidentified as French Canadian or Franco-American, or who indicated that one or more of their grandparents were of French Canadian or Franco-American background, were included in the study. Samples were obtained with full informed consent, with the persons' knowledge that the information would be used for statistical purposes.
From 10 April 1989 to 11 October 1995 (arbitrarily chosen dates), 1260 men and nonpregnant women with French Canadian background living in Massachusetts were identified for inclusion in this study. Relatives of known TSD or Sandhoff disease homozygotes or heterozygotes were excluded from the study to prevent bias of ascertainment. Subjects who had both Ashkenazi Jewish and French Canadian heritage were also excluded. ENZYME ANALYSIS Heterozygosity for TSD was evaluated using the standard heat inactivation assay with 4-methylumbelliferyl-2-deoxy-2-acetamido-beta-D-g1ucopyranoside as substrate (Sigma Chemical, St Louis, MO). Serum and leucocytes were evaluated for total hex and heat stable (hex B) activities as described. '7 18 • The per cent hex A was calculated as 100 -% heat stable hex (hex B). The diagnostic criteria for the serum assay were:~55% hex A = TSD heterozygote; and6 1 % hex A =non-carrier. The criteria for the leucocyte assay were: < 55% hex A = TSD heterozygote; and~62% hex A = non-carrier. Subjects whose results were between the two cut off values were diagnosed as inconclusive, as were those with normal % hex A in serum but low total hex activity «700 units). Samples from people who were inconclusive or carriers by the serum assay were then subjected to the leucocyte assay when leucocytes were available. The criteria for diagnosis of Sandhoff disease heterozygosity were: serum assay,~70% hex A and7 00 units of total activity; leucocyte assay, 70% hex A and~1200 units of specific activity. These diagnostic criteria were determined in our laboratory based on analyses of samples from obligate heterozygotes for TSD or Sandhoff disease.
STATISTICAL ANALYSIS
Confidence intervals for proportions were determined using z statistics; corrections were made for small sample sizes when necessary and 95% was used as the level of confidence. Heterozygosity for Tay-Sachs and Sandhoff diseases 
Religion by birth
Results
ANALYSIS OF~HEXOSAMINIDASE ACTIVITY
Of 1260 samples analysed, 22 TSD heterozygotes were identified with the enzyme assay, yielding a heterozygote frequency of 1 in 57 (CI 1 in 41, 1 in 98). Table 1 shows the total hex and % hex A results for these samples. Eighteen subjects were found to be inconclusive, based on analyses of both serum and leucocyte hex activity. This provided a diagnostic inconclusive rate of 1 in 70, or 1.4%. We also identified eight definite Sandhoff disease carriers (table 2) . Consequently, a minimum frequency of Sandhoff disease heterozygosity, based on enzyme analysis, was 1 in 158 (CI 1 in 93, 1 in 504). We also identified three additional persons who, based on their serum enzyme activities (table 2) , may be Sandhoff disease heterozygotes. However, leucocytes were not received for confirmation of that diagnosis. If those three persons are included in our data set as heterozygotes, the frequency of Sandhoff heterozygosity in this population is 1 in 114 (Cl 1 in 72, 1 in 280).
Discussion
This is the first prospective study to evaluate the frequencies of heterozygosity for Tay-Sachs 135 and Sandhoff diseases among persons of French Canadian background living in the United States. Twenty two of 1260 Massachusetts residents with French Canadian background (1 in 57, or 1.75%) were noted to be heterozygotes for TSD based on biochemical (enzyme) analyses. This is about one half of the frequency found in Ashkenazi Jews living in Massachusetts" and one quarter of the frequency reported for unrelated French Canadians in Eastern Quebec." However, it is significantly higher than the reported general population frequency of 1 in 170 to 1 in 300.' 5 A previous study reported mutation analysis of the hex A gene for 13 of the 22 heterozygotes described in this study. ie TSD causing mutations were identified in five of those samples; three samples had the 7.6 kb deletion, one had the C409T substitution," and one had the C508T substitution." Two samples had benign mutations, five had mutations of unknown significance, and no mutation was detected in one sample. Five additional samples from the 22 TSD heterozygotes have since been analysed by evaluation for the presence of seven known mutations." One sample had the exon 11 +TATC 1278 insertion TSD causing mutation," one had a benign C745T mutation,' two had a G748A substitution, a mutation of unknown significance, is and no mutation was identified in one sample. Leucocytes were not available for mutation analysis for four of the enzyme defined TSD heterozygotes identified in this study.
The finding of six deleterious mutations in this data set provide a minimum frequency of heterozygosity for deleterious alleles at the TSD locus ofl in 210 (CI 1 in 117, 1 in 1050), for persons of French Canadian background in Massachusetts. Elimination of the three subjects with known benign mutations (and inclusion of all the other enzyme defined carriers) gives a maximum TSD heterozygote frequency of 19 in 1260 or 1 in 66 (Cl 1 in 46,1 in 120). Further studies on the in vivo significance of the novel mutations identified in this group" to determine if they are pseudodeficiency or deleterious alleles, and additional evaluation of the two samples without detected mutations will be helpful to provide additional information about the risk of TSD heterozygosity in this population.
These data show that the frequency of heterozygosity for TSD in persons of French Canadian background in Massachusetts is higher than that of the general population. We cannot extrapolate from the Massachusetts data to all of New England because of differences in migration patterns of the French Canadians who originated from various parts of Quebec and moved to various regions of New England." We are in the process of compiling prospective data for the other New England states to determine if the frequency of TSD heterozygosity is increased among people of French Canadian background in those states as well. A previous retrospective study," based on analysis of death certificates from the three northernmost New England states (Maine, New Hampshire, Vermont), determined that the frequency of heterozgosity for TSD among persons of French Canadian background in those states was less than the frequency among Ashkenazi Jews. However, that study could not provide a specific measure of the frequency of heterozygosity for TSD in the population studied, nor are the conclusions from that study necessarily pertinent to French Canadians from other states in New England.
Of the 16 samples in which mutations were found, only three contained the 7.6 kb deletion, indicating that TSD heterozygote screening based on detection of that particular deletion would lack sensitivity in persons of French Canadian background living in Massachusetts. Addition of analyses for the three most common mutations found in Ashkenazi Jewish heterozygotes would provide only a minimal increase in sensitivity as only one of our patients had one of those mutations. Thus, it is clear that the enzyme assay is a more sensitive screening test for TSD heterozygosity in persons of French Canadian background from Massachusetts, as well as in other non-Jewish populations. 10 In addition, the simultaneous screening for TSD and Sandhoff disease heterozygosity is another advantage of the hex enzyme assay over mutation analysis for routine TSD carrier testing in this population.
Several interesting findings arise from the biochemical data from this patient group. For example, one DNA documented heterozygote had a normal % hex A in serum (sample 16). However, that peson had low total activity in serum (575 units), which led us to assay the leucocyte hex activity. The results of the latter, in turn, clearly indicated that this person was a TSD heterozygote. This emphasises the need to perform a bivariate analysis, taking into consideration both % hex A and total activity. Laboratories that rely solely on serum % hex A for diagnostic purposes may misdiagnose such people.
This study also identified a frequency of 1 in 114 for Sandhoff disease heterozygosity in persons of French Canadian background living in Massachusetts. This is higher than the heterozygote frequency previously reported for the general population, 1 in 278. 1 Taken together, our data provide for a maximum frequency of TSD or Sandhoff disease heterozygosity of 1 in 42 (CI 1 in 31, 1 in 64) among people of French Canadian background living in Massachusetts.
In view of the serious nature of Tay-Sachs and Sandhoff diseases, the high sensitivity of the biochemical screening test and the increased heterozygote frequency among persons of French Canadian background living in Massachusetts relative to the general population risk, there is a need for discussion regarding the appropriateness of routinely offering carrier screening for~hexosaminidase deficiency disorders to this population. Such discussion should be sensitive to the interests and needs of the at-risk group and consider as well other scientific and economic issues that arise in evaluating any screening programme."
